B Group, Inc. 13F holdings, Q1 2026
Holdings as of March 31, 2026 · filings on SEC EDGAR · latest filing →
B Group, Inc. disclosed 20 US equity positions worth $134.9m in its Q1 2026 13F filing. The largest position was ADMA at 21.4% of the reported book, followed by PALI and PRAX.
What did B Group, Inc. own in Q1 2026? Top 20 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs prior |
|---|---|---|---|---|---|---|---|
| 1 | ADMA ADMA BIOLOGICS INC | Healthcare | 21.4% | $28.9m | 3,207,542 | – | |
| 2 | PALI PALISADE BIO INC | Healthcare | 14.8% | $20.0m | 11,414,285 | – | |
| 3 | PRAX PRAXIS PRECISION MEDICINES I | Healthcare | 7.9% | $10.7m | 33,237 | – | |
| 4 | CLLS CELLECTIS S A | 7.7% | $10.4m | 3,281,501 | – | ||
| 5 | ZLAB ZAI LAB LTD | Healthcare | 6.3% | $8.5m | 450,646 | – | |
| 6 | TSHA TAYSHA GENE THERAPIES INC | Healthcare | 6.0% | $8.0m | 1,800,556 | – | |
| 7 | NRXP NRX PHARMACEUTICALS INC | 4.7% | $6.4m | 3,000,000 | – | ||
| 8 | GPCR STRUCTURE THERAPEUTICS INC | Healthcare | 4.6% | $6.1m | 127,500 | – | |
| 9 | IOVA IOVANCE BIOTHERAPEUTICS INC | Healthcare | 3.9% | $5.3m | 1,500,000 | – | |
| 10 | SYRE SPYRE THERAPEUTICS INC | Healthcare | 3.7% | $5.0m | 100,000 | – | |
| 11 | DRUG BRIGHT MINDS BIOSCIENCES INC | Healthcare | 3.7% | $4.9m | 67,500 | – | |
| 12 | ASMB ASSEMBLY BIOSCIENCES INC | Healthcare | 3.6% | $4.9m | 175,706 | – | |
| 13 | AURA AURA BIOSCIENCES INC | 3.0% | $4.0m | 597,576 | – | ||
| 14 | ORKA ORUKA THERAPEUTICS INC | Healthcare | 2.7% | $3.7m | 75,000 | – | |
| 15 | SGHT SIGHT SCIENCES INC | 2.7% | $3.7m | 970,000 | – | ||
| 16 | RARE ULTRAGENYX PHARMACEUTICAL IN | Healthcare | 2.1% | $2.8m | 135,000 | – | |
| 17 | APGE APOGEE THERAPEUTICS INC | Healthcare | 0.5% | $631.3k | 7,500 | – | |
| 18 | FHTX FOGHORN THERAPEUTICS INC | Healthcare | 0.4% | $487.6k | 102,000 | – | |
| 19 | SLNOEUR SOLENO THERAPEUTICS INC | 0.2% | $251.1k | 7,500 | – | ||
| 20 | REPL REPLIMUNE GROUP INC | Healthcare | 0.1% | $198.9k | 26,000 | – |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.